EUVIMEDEUVIMED entdecken
Crossref

Angiotensin-Converting Enzyme Inhibitor Washout Period Prior to Angiotensin Receptor/Neprilysin Inhibitor Initiation in the Inpatient Setting

Kaanan Shah, Stella Mabhugu, Jessica Obioma, Quang Nguyen, Jessica Schillig, Brittany P Torres iD, Meredith Howard iD, Bryn Lindley iD

Annals of Pharmacotherapy · 2025

DOI: 10.1177/10600280241282324 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Pharmacotherapy, 2025. Verfasst von Kaanan Shah und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, The University of North Texas Health Science Center, Fort Worth, TX, USA. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Antagonists, Neprilysin, Heart Failure. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben. Gefördert von: HCA Healthcare and/or an HCA Healthcare affiliated entity.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The 2022 AHA-ACC HFSA Guideline for Management of Heart Failure recommend initiating an angiotensin receptor/neprilysin inhibitor (ARNI) in patients with heart failure with reduced ejection fraction (HFrEF) who can tolerate an angiotensin-converting enzyme inhibitor (ACEi). The manufacturer recommends initiating a 36-hour washout period when switching from ACEi to ARNI due to an increased risk of adverse effects, including angioedema. This study investigated the adherence to the washout period when transitioning from ACEi to ARNI at a community hospital.

Objectives

The primary objective was to assess the rate of adherence to the 36-hour washout when transitioning patients from ACEi to ARNI. Secondary outcomes included heart failure exacerbation readmission rates within 90 days and the rate of adverse effects (angioedema, hypotension, acute kidney injury, and hyperkalemia).

Methods

This was a retrospective cohort study including patients with HFrEF who were transitioned from ACEi to ARNI during their hospital stay between March 1, 2016 and December 31, 2022. Patients were excluded if they did not receive an ACEi or ARNI during their admission or if they had an ejection fraction >40%. Pearson chi-square was used to analyze categorical data.

Results

Of 33 patients included in this study, 67% received the full 36-hour washout period when transitioning from ACEi to ARNI. There were no significant differences between the rates of hospital readmissions or adverse effects between the groups. No patients experienced hyperkalemia or angioedema. Conclusion and Relevance: This is the first study to our knowledge to describe real-world prescribing practices when transitioning patients from ACEi to ARNI for the treatment of HFrEF. Larger, multicenter studies are needed to provide more data on prescribing practices outside this single center. Future research should also include pharmacist’s role in adhering to the recommended washout.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsNeprilysinHeart FailureDrug SubstitutionHumansMaleRetrospective StudiesFemaleAgedMiddle AgedInpatientsPatient ReadmissionAngioedemaGuideline AdherenceAged, 80 and over

Stichwörter der Autor:innen

ACE inhibitorsangiotensin II receptor antagonistscardiologycongestive heart failuredrug safety

Substanzen

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsNeprilysin

Autor:innen und Institutionen

  • College of Pharmacy, The University of North Texas Health Science Center, Fort Worth, TX, USA.
  • Henry Ford Hospital, Henry Ford Health, Detroit, MI, USA.
  • MountainView Hospital, Las Vegas, NV, USA.
  • Supply Chain, HealthTrust, Nashville, TN, USA.
  • Medical City Fort Worth Hospital, Fort Worth, TX, USA.
  • Amgen, Thousand Oaks, CA, USA.

ORCID-Profile: Brittany P Torres, Meredith Howard, Bryn Lindley

Förderung

  • HCA Healthcare and/or an HCA Healthcare affiliated entity

Zitieren

APA

Shah, K., Mabhugu, S., Obioma, J., Nguyen, Q., Schillig, J., Torres, B. P., Howard, M., & Lindley, B. (2025). Angiotensin-Converting Enzyme Inhibitor Washout Period Prior to Angiotensin Receptor/Neprilysin Inhibitor Initiation in the Inpatient Setting. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280241282324

Vancouver

Shah K, Mabhugu S, Obioma J, Nguyen Q, Schillig J, Torres BP, et al. Angiotensin-Converting Enzyme Inhibitor Washout Period Prior to Angiotensin Receptor/Neprilysin Inhibitor Initiation in the Inpatient Setting. Annals of Pharmacotherapy. 2025. doi:10.1177/10600280241282324

BibTeX
@article{Shah2025,
  author = {Shah, Kaanan and Mabhugu, Stella and Obioma, Jessica and Nguyen, Quang and Schillig, Jessica and Torres, Brittany P and Howard, Meredith and Lindley, Bryn},
  title = {Angiotensin-Converting Enzyme Inhibitor Washout Period Prior to Angiotensin Receptor/Neprilysin Inhibitor Initiation in the Inpatient Setting},
  journal = {Annals of Pharmacotherapy},
  year = {2025},
  doi = {10.1177/10600280241282324}
}
Kostenlos starten →